A Phase 2, Randomized, Open-Label Study To Assess The Safety And Efficacy Of Weekly (QW) Or Once Every Two Week (Q2W) Dosing Of Epoetin Alfa (PROCRIT) in Anaemic Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Trial Profile

A Phase 2, Randomized, Open-Label Study To Assess The Safety And Efficacy Of Weekly (QW) Or Once Every Two Week (Q2W) Dosing Of Epoetin Alfa (PROCRIT) in Anaemic Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 19 May 2014 New trial record
    • 22 May 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top